[go: up one dir, main page]

PL2825528T3 - Podstawione pirolidyno-2-karboksyamidy - Google Patents

Podstawione pirolidyno-2-karboksyamidy

Info

Publication number
PL2825528T3
PL2825528T3 PL13708466T PL13708466T PL2825528T3 PL 2825528 T3 PL2825528 T3 PL 2825528T3 PL 13708466 T PL13708466 T PL 13708466T PL 13708466 T PL13708466 T PL 13708466T PL 2825528 T3 PL2825528 T3 PL 2825528T3
Authority
PL
Poland
Prior art keywords
carboxamides
substituted pyrrolidine
pyrrolidine
substituted
Prior art date
Application number
PL13708466T
Other languages
English (en)
Inventor
Daniel Fishlock
David Joseph Bartkovitz
Xin-Jie Chu
Binh Thanh Vu
Chunlin Zhao
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL2825528T3 publication Critical patent/PL2825528T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polyethers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13708466T 2012-03-15 2013-03-12 Podstawione pirolidyno-2-karboksyamidy PL2825528T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261611200P 2012-03-15 2012-03-15

Publications (1)

Publication Number Publication Date
PL2825528T3 true PL2825528T3 (pl) 2017-09-29

Family

ID=47844360

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13708466T PL2825528T3 (pl) 2012-03-15 2013-03-12 Podstawione pirolidyno-2-karboksyamidy

Country Status (27)

Country Link
US (1) US8993614B2 (pl)
EP (1) EP2825528B1 (pl)
JP (1) JP6125546B2 (pl)
KR (1) KR20140138165A (pl)
CN (1) CN104271554B (pl)
AR (1) AR090328A1 (pl)
AU (1) AU2013203662B2 (pl)
BR (1) BR112014018959A8 (pl)
CA (1) CA2860781A1 (pl)
CL (1) CL2014001858A1 (pl)
CO (1) CO6990736A2 (pl)
CR (1) CR20140399A (pl)
DK (1) DK2825528T3 (pl)
EA (1) EA025557B1 (pl)
ES (1) ES2634290T3 (pl)
HU (1) HUE032864T2 (pl)
IL (1) IL234173A (pl)
MX (1) MX2014010942A (pl)
NZ (1) NZ626505A (pl)
PE (1) PE20142185A1 (pl)
PH (1) PH12014501542B1 (pl)
PL (1) PL2825528T3 (pl)
SG (1) SG11201404344XA (pl)
SI (1) SI2825528T1 (pl)
TW (1) TWI586648B (pl)
UA (1) UA113541C2 (pl)
WO (1) WO2013135648A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406889WA (en) 2012-05-30 2015-02-27 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
JP6346945B2 (ja) * 2013-06-24 2018-06-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 安定な静脈内製剤
HK1215453A1 (zh) 2013-07-03 2016-08-26 豪夫迈.罗氏有限公司 用於将用mdm2拮抗剂进行患者癌症治疗个人化的基於mrna的基因表达
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
WO2015082384A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
PL3459933T3 (pl) * 2014-04-15 2023-01-23 F. Hoffmann-La Roche Ag Stałe postacie farmaceutycznie czynnego związku
JP2017520526A (ja) * 2014-05-22 2017-07-27 ザ・ユニバーシティ・オブ・シドニー オメガ−3類似体
WO2016055497A1 (en) * 2014-10-10 2016-04-14 F. Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
CN104496822B (zh) * 2014-12-15 2016-10-26 扬州三友合成化工有限公司 一种1-氯乙基环己基丙基碳酸酯的制备方法
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
CN107698598B (zh) * 2016-08-08 2019-06-21 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ, スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
CA3086522A1 (en) * 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
CN114230561B (zh) * 2020-09-09 2024-03-19 中国人民解放军海军军医大学 一种mdm2抑制剂类小分子化合物及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
DE69120141T2 (de) 1990-03-28 1996-11-28 Shuji Kojima Polymerkombiniertes Arzneimittel zur Magenbehandlung und Verfahren zu dessen Herstellung
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
WO1995016465A1 (en) 1993-12-14 1995-06-22 Sandoz Ltd. Pharmaceutical compositions containing alkyl polyoxyalkylene carboxylates
DE4435087A1 (de) 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
AU9402198A (en) 1997-09-26 1999-04-23 Becton Dickinson & Company Preparing conjugates using polyethylene glycol linkers
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US20040171808A1 (en) 2001-05-30 2004-09-02 Kazunori Kataoka Method of bonding substance to be incorporated into polymer terminal
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
MXPA04006855A (es) 2002-01-18 2005-04-19 Biogen Idec Inc Compuestos de polimeros de polialquileno y usos de los mismos.
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
JP4991037B2 (ja) 2004-04-01 2012-08-01 カーディオム ファーマ コーポレイション イオンチャネル調節化合物を含む薬物結合体
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006047419A2 (en) 2004-10-25 2006-05-04 Intezyne Technologies, Incorporated Heterobifunctional poly(ethylene glycol) and uses thereof
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
CA2650035C (en) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
WO2008109783A2 (en) 2007-03-06 2008-09-12 The Regents Of The University Of California Detecting spin perturbations using magnetic resonance imaging
CN101357986B (zh) 2007-06-13 2013-06-05 康达医药科技有限公司 聚乙二醇功能性衍生物和制造方法
WO2009128789A1 (en) 2008-04-17 2009-10-22 Agency For Science, Technology And Research Vesicles for intracellular drug delivery
US20110104074A1 (en) 2008-06-18 2011-05-05 University Of Louisville Research Foundation, Inc. Methods for targeted cancer treatment and detection
MY155612A (en) 2008-07-14 2015-11-13 Biocon Ltd A method of synthesizing a substantially monodispersed mixture of oligomers
US8653131B2 (en) 2008-08-22 2014-02-18 Baxter Healthcare S.A. Polymeric benzyl carbonate-derivatives
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
KR101380013B1 (ko) 2008-09-18 2014-04-10 에프. 호프만-라 로슈 아게 치환 피롤리딘-2-카르복사미드
US8709467B2 (en) 2009-06-26 2014-04-29 Cute Lovable Teddy Bear, Llc. Para-xylylene based microfilm elution devices
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
CN101991860B (zh) 2010-11-08 2013-06-19 中国药科大学 泊洛沙姆-羧酸类药物偶联物及其制备方法与应用
TWI535723B (zh) 2010-11-12 2016-06-01 密西根大學董事會 螺-吲哚酮mdm2拮抗劑
CA2825926A1 (en) 2011-02-02 2012-08-09 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
US9212258B2 (en) 2011-02-23 2015-12-15 The Board Of Trustees Of The University Of Illinois Amphiphilic dendron-coils, micelles thereof and uses
CN102247602B (zh) 2011-06-13 2013-01-02 中山大学 一种超分子水凝胶双重药物载体及其制备方法和应用
AU2012301793A1 (en) 2011-08-30 2014-03-20 Quanta Biodesign, Ltd. Branched discrette PEG constructs
SG11201406889WA (en) * 2012-05-30 2015-02-27 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
BR112014018959A2 (pl) 2017-06-20
US20130244958A1 (en) 2013-09-19
SI2825528T1 (sl) 2017-08-31
HK1200830A1 (en) 2015-08-14
CN104271554A (zh) 2015-01-07
PH12014501542A1 (en) 2014-09-22
TWI586648B (zh) 2017-06-11
BR112014018959A8 (pt) 2017-07-11
JP2015512890A (ja) 2015-04-30
TW201341357A (zh) 2013-10-16
EA025557B1 (ru) 2017-01-30
US8993614B2 (en) 2015-03-31
HUE032864T2 (en) 2017-11-28
AR090328A1 (es) 2014-11-05
SG11201404344XA (en) 2014-10-30
PE20142185A1 (es) 2014-12-29
NZ626505A (en) 2016-04-29
AU2013203662B2 (en) 2016-04-14
ES2634290T3 (es) 2017-09-27
JP6125546B2 (ja) 2017-05-10
DK2825528T3 (en) 2017-08-14
PH12014501542B1 (en) 2014-09-22
CR20140399A (es) 2014-10-07
IL234173A (en) 2017-08-31
CL2014001858A1 (es) 2014-09-26
UA113541C2 (xx) 2017-02-10
MX2014010942A (es) 2014-11-14
EP2825528A1 (en) 2015-01-21
CA2860781A1 (en) 2013-09-19
CO6990736A2 (es) 2014-07-10
EP2825528B1 (en) 2017-05-24
AU2013203662A1 (en) 2013-10-03
KR20140138165A (ko) 2014-12-03
CN104271554B (zh) 2016-11-23
EA201491623A1 (ru) 2014-12-30
WO2013135648A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
DK3327112T3 (en) Agse-deficient stamme
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
EP2935220A4 (en) PERI-carbinol
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB201203307D0 (en) Remvox
GB201205346D0 (en) Loadwatch
AU345893S (en) Treehouse
GB201205953D0 (en) SmartMat
GB201205354D0 (en) Herbscan bookcradle
GB201205311D0 (en) InternalGCN
GB201205034D0 (en) Boozshooz
GB201204911D0 (en) Superswoosher
GB201204748D0 (en) Toretear
GB201204316D0 (en) Comniview
GB201204245D0 (en) MobiKey
GB201204164D0 (en) Plugstop
GB201204088D0 (en) Tidythatcable
GB201203844D0 (en) Salvacubo
GB201203777D0 (en) Quit-clip
GB201203776D0 (en) Sili-m8
GB201203808D0 (en) MicBooth
GB201203815D0 (en) Mini-meals
GB201203604D0 (en) Envelope-box